JPMorgan Chase & Co. reduced its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 18.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 624,365 shares of the medical instruments supplier’s stock after selling 144,858 shares during the period. JPMorgan Chase & Co. owned about 1.68% of AngioDynamics worth $13,574,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Meeder Asset Management Inc. boosted its position in shares of AngioDynamics by 729.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 6,529 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 5,742 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at about $191,000. Crossmark Global Holdings Inc. acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at about $205,000. Sun Life Financial INC acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at about $231,000. Finally, SG Americas Securities LLC acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at about $336,000.
ANGO has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. BidaskClub upgraded shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 8th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $18.44.
In other AngioDynamics news, CFO Michael Greiner sold 1,939 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $21.53, for a total value of $41,746.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.80% of the stock is owned by insiders.
NASDAQ:ANGO opened at $20.78 on Friday. The stock has a market capitalization of $776.96 million, a price-to-earnings ratio of 28.08 and a beta of 0.78. AngioDynamics, Inc. has a 12 month low of $15.16 and a 12 month high of $24.49. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). The firm had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the firm earned $0.13 earnings per share. Research analysts predict that AngioDynamics, Inc. will post 0.85 earnings per share for the current fiscal year.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
See Also: How to invest in a bear market
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.